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Abstract
Recent evidences suggest the involvement of DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1 A)
in Alzheimer’s disease (AD). Here we showed that DYRK1A undergoes a proteolytic processing in AD patients
hippocampus without consequences on its kinase activity. Resulting truncated forms accumulate in astrocytes and
exhibit increased affinity towards STAT3ɑ, a regulator of inflammatory process. These findings were confirmed in APP/
PS1 mice, an amyloid model of AD, suggesting that this DYRK1A cleavage is a consequence of the amyloid pathology.
We identified in vitro the Leucettine L41 as a compound able to prevent DYRK1A proteolysis in both human and
mouse protein extracts. We then showed that intraperitoneal injections of L41 in aged APP/PS1 mice inhibit STAT3ɑ
phosphorylation and reduce pro-inflammatory cytokines levels (IL1- β, TNF-ɑ and IL-12) associated to an increased
microglial recruitment around amyloid plaques and decreased amyloid-β plaque burden. Importantly, L41 treatment
improved synaptic plasticity and rescued memory functions in APP/PS1 mice. Collectively, our results suggest that
DYRK1A may contribute to AD pathology through its proteolytic process, reducing its kinase specificity. Further
evaluation of inhibitors of DYRK1A truncation promises a new therapeutic approach for AD.
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Introduction
Despite considerable academic and pharmaceutical in-
vestments during the last three decades, there is still no
effective treatment for Alzheimer’s disease (AD). AD
neuropathology is mostly defined by the accumulation of
amyloid-beta (Aβ) plaques and neurofibrillary tangles
(NFTs) in patient brains. Extracellular Aβ plaques are
mainly formed by the aggregation of amyloid peptides
(Aβ40 and Aβ42) whose production and accumulation
are key elements in AD development [15]. Intracellular
NFTs are composed of aggregated hyper- and abnormal
phosphorylated Tau proteins. Accumulating data from
preclinical and clinical studies have established that
several immune system-mediated factors, mainly driven
by glial cells, also contribute to AD pathogenesis. Astro-
cytes and microglia surround amyloid plaques and re-
lease cytokines leading to inflammatory processes whose
dysregulation contributes to AD pathology [19, 37, 38].
Dual-specificity tyrosine-phosphorylation-regulated
kinase 1A (DYRK1A), encoded by a gene localized in the
Down syndrome critical region of chromosome 21, is a
serine/threonine protein kinase which contributes to
various biological processes in the embryonic and adult
central nervous systems [39]. In AD, DYRK1A is espe-
cially known to phosphorylate Tau at several sites in-
cluding Thr181, Thr212, and Thr231, which are all
observed in NFTs of AD brains [29, 33, 46] and the
amyloid precursor protein (APP) at Thr-668 [34] or the
presenilin 1 (PS1) at Thr-354 [36]. DYRK1A also phos-
phorylates several immune response mediators associ-
ated with AD, including calcineurin-nuclear factor of
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activated T cells (NFAT) [1] and signal transducer and
activator of transcription-3 (STAT3) [26]. Recent study
showed that DYRK1A inhibition reduces APP phosphor-
ylation and insoluble Tau phosphorylation and thereby
reverse cognitive deficits in AD mice [3]. However, pre-
vious contradictory studies have been published [11, 23]
and further study are required to confirm the DYRK1A
protein levels in brain of individuals with AD. Further-
more, it is emphasized that level of its kinase activity is
still unknown. Thus, the relevance of inhibiting kinase
activity of DYRK1A in AD remains a matter of debate.
Here, we show that DYRK1A is truncated in the AD
context. This increase of truncated forms of DYRK1A
(DYRK1AT) is associated with a decrease of full-length
form of DYRK1A (DYRK1AFL) thus confirming previous
report by Jin and colleagues [23]. This was observed in
hippocampus from AD patients but also in APP/PS1
mice, an amyloid mouse model of AD [22]. We demon-
strated for the first time that this proteolysis is occurring
in astrocytes and is not associated with a modification of
the global DYRK1A kinase activity in AD. In vitro, we
show that, compared to DYRK1AFL, DYRK1AT exhibit
stronger affinity toward STAT3ɑ. We identified Leucet-
tine L41, derived from the marine sponge alkaloid Leucet-
tamine B [8, 41], as an appropriate compound to inhibit
DYRK1A proteolysis. To decipher the effects of DYRK1A
proteolysis and its inhibition in vivo, we treated APP/PS1
mice with the leucettine L41. We show in the present
study that L41 prevents DYRK1A proteolysis and reduces
STAT3ɑ phosphorylation in APP/PS1 mice. Neuroinflam-
mation, amyloid plaque load, synaptic plasticity and cogni-
tive functions are improved. Altogether, our results
confirm the involvement of DYRK1AT in AD pathology
and demonstrate the relevance of inhibitors of DYRK1A
cleavage as a potentially relevant therapeutic strategy.
Material and methods
Animals
Fourteen APPswe/PS1ΔE9 mice (referred to as APP/
PS1; Jackson Laboratories) and 12 age-matched litter-
mate control mice were used for behavioral (Morris
Water Maze), pathology, and biochemistry studies. A
second cohort composed of 14 APP/PS1 and nine lit-
termates were used for behavioral (Y-maze) and elec-
trophysiological analysis. APP/PS1 mice express the
human APP gene carrying the Swedish double muta-
tion (K595 N/M596 L). In addition, they express the
human PS1ΔE9 variant lacking exon 9 [22]. Only
male mice were used. The ages at treatment and ana-
lysis/sacrifice are given in the Results section. All ex-
periments were conducted in accordance with the
ethical standards of French, German, and European
regulations (European Communities Council Directive
of 24 November 1986). The supervisor of in vivo
studies (J Braudeau) received official authorization
from the French Ministry of Agriculture to carry out
research and experimentation on animals
(authorization number APAFIS#4449–2,016,031,012,
491,697).
Tissue collection and sample preparation
Mice were anesthetized with ketamine/xylazine (100 and
10mg/kg respectively) and decapitated. One hemisphere
was post-fixed by incubation for 72 h in 4% PFA, cryo-
protected in 30% sucrose in PBS, and cut into 40 μm
sections with a freezing microtome (Leica) for histo-
logical analyses. The contralateral hemisphere was dis-
sected for hippocampus isolation. Samples were
homogenized in a lysis buffer (150 mM NaCl and 1%
Triton in Tris-buffered saline) containing phosphatase
(Pierce) and protease (Roche) inhibitors and centrifuged
for 20 min at 15000 x g. The same procedure was ap-
plied to human samples.
Leucettine L41 treatment
The pre-weighed compound was dissolved in DMSO/
PEG300/water (5/35/60) to a final concentration of 2mg/
mL for a dose of 20mg/kg. The formulation was prepared
on the day of the in vivo experiment. The mice received
five intraperitoneal injections per week for four weeks.
DYRK1A in vitro proteolysis
Human hippocampus tissue and 4months-aged mouse
(C57Bl6) hippocampus were homogenized in 9 volumes
of buffer consisting of 50 mM Tris-HCl (pH 7.4), 8.5%
sucrose, 10 mM β-mercaptoethanol, 2.0 mM EDTA,
followed by centrifugation at 16,000×g at 4 °C for 10
min. The supernatants were incubated in the presence
or absence of various concentrations of Ca2+ with or
without Harmine, Leucettine LeuI or Leucettine L41 at
various concentrations (0.1; 1.0 or 2.0 μM) for 10min at
30 °C. The reactions were terminated by the addition of
4-fold concentrated SDS-PAGE sample buffer, followed
by heating in boiling water for 5 min. The products of
proteolysis were analyzed by Western blots developed
with antibody to DYRK1A.
Identification of DYRK1A interactions
Homogenized total proteins from mouse hippocampus
tissue were incubated with 2 mM EDTA, 0 or 2 mM of
Ca2+ and 0 or 1 μM of Leucettine L41 during 10min at
30 °C. 200 μg of total proteins were incubated with 2 μg
of α-DYRK1A-Nter antibody (DYRK1A D1694) over-
night at 4 °C. The proteins interacting with DYRK1A
were revealed by Western blots developed with STAT3
(1/1000, Cell Signaling), NFATc1 (1/1000, Cell Signal-
ing), APP, Tau and PS1.
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Western blotting
Equal amounts of protein (30 μg) were separated by elec-
trophoresis in NuPAGE Bis-Tris Gels (Life Technolo-
gies) and transferred to nitrocellulose membranes. The
membranes were hybridized with various primary anti-
bodies (DYRK1A 7D10 (1/250, Abnova), DYRK1A
D1694 (1/500, Sigma), GFAP (DAKO, 1/4000), Vimentin
(1/1000, Abcam), pSTAT3(Y705) (1/1000, Cell Signal-
ing), STAT3 (1/1000, Cell Signaling), IBA1 (1/2000,
Wako), CD68 (1/1000, BioLegend), IDE (1/200, Santa
Cruz), TREM2 (R&D Systems, 1/500), GAPDH (1/1000,
Abcam)). Various secondary antibodies were also used
(ECL Anti-mouse horseradish peroxidase linked, 1/2000,
GE Healthcare; ECL Anti-rabbit horseradish peroxidase
linked, 1/2000, GE Healthcare). Membranes were devel-
oped using enhanced chemiluminescence (Thermo Fisher
Scientific). Signals were detected with Fusion FX7 (Vilber
Lourmat) and analyzed and quantified using ImageJ (NIH).
Elisa
Inflammatory cytokines and interleukin concentrations
were measured using the MSD Mouse V-PLEX Plus Pro-
inflammatory Panel 1 kit (Meso Scale Diagnostics). Ex-
tracted soluble Aβ forms were quantified with the MSD
Human and rodents V-Plex Plus Aβ Peptide Panel 1
(4G8) (Meso Scale Diagnostics). All ELISA were per-
formed according to each kit manufacturer’s instructions.
Calpain activity
Calpain activity was measured using the fluorogenic
peptide
N-Succinyl-Leu-Tyr-7-Amido-4-Methylcoumarin as de-
scribed by Kohli et al. [25]. Briefly, 60 μg brain extract in
a final volume of 40 μL was added to 160 μL 50 μM
N-Succinyl-Leu-Tyr-7-Amido-4-Methylcoumarin dis-
solved in dimethyl sulfoxide and Tris buffer (100 mM
Tris-HCl, 145mM NaCl at pH 7.3). Proteolysis of the
substrate was monitored for 21 min at room
temperature with a FlexStation3 multi-mode microplate
reader (excitation: 380 nm, emission: 460 nm; Molecular
Devices) either in the presence of 10 mM Ca2+ or 10
mM EGTA to determine calcium-independent activity,
thus excluding cathepsin activity.
DYRK1A kinase activity assay
Catalytic activity of total and endogenous DYRK1A
was assessed using high-performance liquid chroma-
tography (HPLC), based on the separation and quan-
tification of specific fluorescent peptides (substrate
and phosphorylated product), as previously described
[4]. Both negative (without protein) and positive con-
trols (DYRK1A recombinant protein) have been used
to determine background and to check the specificity
of the kinase activity assay.
Immunohistochemistry and image acquisition
Cryosections were washed with 0.25% Triton in 0.1M
PBS, incubated in an 88% formic acid solution for 15
min (antigen retrieval), and saturated by incubation in
0.25% Triton in 0.1M PBS/5% goat serum. They were
then incubated with primary antibodies (DYRK1A 7D10
(1/100, Abnova), DYRK1A D1694 (1/100, Sigma), GFAP
(DAKO, 1/2000), APP 4G8-Biotin, (1/1000, Covance),
IBA1 (1/500, Wako)). For non-fluorescent immunostain-
ing, endogenous peroxidase was quenched with PBS
containing 3% H2O2 for 5 min, followed by amplification
using the ABC system (VECTASTAIN Elite ABC HRP
Kit, Vector Laboratories, Burlingame, CA, USA). Horse-
radish peroxidase conjugate and 3,3′-diaminobenzidine
were then used according to the manufacturer’s manual
(Vector® DAB, Vector Laboratories, Burlingame, CA,
USA). The sections were mounted, dehydrated by pass-
ing twice through ethanol and toluol solutions, and
cover-slipped with Eukitt (O. Kindler). Images were cap-
tured with a Leica DM6000 microscope and analyzed
using ImageJ software (NIH). For fluorescent immunos-
tainings, slices were incubated with secondary Alexa
Fluor conjugated antibodies (Invitrogen). Slices were
stained with DAPI (1/5000, Sigma), mounted in Vecta-
shield fluorescent mounting media (Vector laboratories)
and conserved at 4 °C. Images were captured with a
Leica SP8 confocal microscope (Leica) and analyzed
using ImageJ software (NIH). Laser power, numeric gain,
and magnification were kept constant between animals
to avoid potential technical artefacts. Images were first
converted to 8-bit gray scale and binary thresholded to
highlight positive staining. At least three sections per
mouse (between − 1.7 mm to − 2.3 mm caudal to
Bregma) were quantified. The average value per struc-
ture was calculated for each mouse. For quantification of
Iba1 and GFAP immunoreactivity around plaques, a re-
gion of interest (ROI) was drawn around the center of
the plaque. The diameter of the circular ROI was set to
two times the diameter of the plaque. Mean fluorescence
intensity values were measured for either DYRK1A
(7D10) (α-DYRK1A-Cter), DYRK1A (D1694) (α-DYR-
K1A-Nter) Iba1, or GFAP immunoreactivity and were
processed using Icy software (Institut Pasteur, Paris,
France). Experiments and data analysis were performed
blind with respect to treatments and genotypes.
Behavioral assessment
Y-maze. Experiments were performed in a maze consist-
ing of three transparent plastic arms, 46 × 11 × 25 cm
each, set at a 120° angle relative to each other. During
the first trial, mice could freely explore two arms, called
familiar arms (FA), for 3 min, whereas the third arm was
blocked by an opaque door. Assignment of arms was
counterbalanced randomly within each experimental
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group to avoid any preference-related bias. Mice were
then returned to their home cage for 5 min. Finally, mice
were returned to the maze and allowed to explore all
three arms, including the novel arm (NA), for 3 min.
The maze was carefully cleaned with a 70% ethanol solu-
tion between each exploration phase to remove any ol-
factory cues. EthoVision software was used for recording
and analysing each exploration trial.
Morris water maze
Experiments were performed in a tank 180 cm in diam-
eter and 50 cm deep, filled with opaque water main-
tained at 21 °C, equipped with a platform of 18 cm in
diameter, submerged 1 cm below the surface of the
water. Visual clues were positioned around the pool and
luminosity was maintained at 350 lx. The mice were ini-
tially exposed to a learning phase, which consisted of
daily sessions (three trials per session) on five consecu-
tive days. The starting position varied pseudo-randomly,
between the four cardinal points. There was a mean
interval of 20 min between trials. The trial was consid-
ered to have ended when the animal reached the plat-
form. Long-term spatial memory was assessed 72 and
120 h after the last training trial in a probe trial in which
the platform was no longer available. Animals were
monitored with EthoVision software.
Ex vivo electrophysiology
Slice preparation. Mice were anesthetized with halothane
and decapitated. The brain was rapidly removed from
the skull and placed in chilled (0–3 °C) artificial cerebro-
spinal fluid (ACSF) containing 124 mM NaCl, 3.5 mM
KCl, 1.5 mM MgSO4, 2.5 mM CaCl2, 26.2 mM
NaHCO3, 1.2 mM NaH2PO4, and 11 mM glucose.
Transverse slices (300–400 μm thick) were cut with a
vibratome and placed in ACSF in a holding chamber, at
27 °C, for at least one hour before recording. Each slice
was individually transferred to a submersion-type re-
cording chamber and submerged in ACSF continuously
superfused and equilibrated with 95% O2, 5% CO2.
Extracellular field recordings
Electrically induced long-term potentiation (LTP) was
studied. Theta-burst stimulation (TBS), mimicking the
natural stimulation at the theta frequency from the med-
ial septum to the hippocampus, consisting of five trains
of four 100 Hz pulses each, separated by 200 ms, was ap-
plied at the test intensity. The sequence was repeated
three times, with an interburst interval of 10s. Testing
with a single pulse was then performed for 60 min (TBS)
or 75min (3 × 100 Hz), to determine the level of LTP.
Statistical analysis
Data are expressed as the mean ± SEM. Statistical analyses
were performed with GraphPad Prism (GraphPad
Soft-ware, La Jolla, CA, USA) software. One-way ANOVA
followed Tukey’s post-hoc tests were used to determine
the significance of differences between groups. Student’s t
test was used when only two groups were analyzed. All
values are given as mean ± SEM. Statistical significance
was set to a P-value < 0.05 for all tests.
Results
DYRK1AT is detected in astrocytes of Alzheimer’s disease
patients
We evaluated DYRK1A proteolysis in hippocampus from
AD patients (Braak V-VI, Thal IV-V) (n = 4) and
age-matched controls (n = 4). Using the anti-DYRK1A
antibody 7D10 (named after α-DYRK1A-Cter) targeting
the C-terminal region of DYRK1A, we observed de-
creased levels of DYRK1A in AD patients compared to
controls (p < 0.05) (Additional file 1: Figure 1A,B).
DYRK1A can be cleaved by calpains [23],
calcium-activated cysteine proteases highly activated in
AD brain [27]. Here, we found that calpain activity was
higher in hippocampus of AD cases compared to con-
trols (p = 0.0571) (Additional file 1: Figure 1C) and sig-
nificantly correlated with DYRK1A protein levels
(correlation coefficient r = − 0.94, p < 0.0005) (Additional
file 1: Figure 1D). However, we observed no difference in
total endogenous DYRK1A catalytic activity using
high-performance liquid chromatography (HPLC) [4]
(Additional file 1: Figure 1E). We performed western
blots using the D1694 antibody targeting the N-terminal
region of DYRK1A (named after α-DYRK1A-Nter) and
we observed decreased levels of the full-length form of
DYRK1A (DYRK1AFL, 90 kDa) associated to an increase
of the truncated form (DYRK1AT, 50 kDa) in the hippo-
campus of AD patients (Additional file 1: Figure 1F). We
then further characterized expression of the different
forms of DYRK1A by immunohistochemistry on hippo-
campal slices. Combining α-DYRK1A-Cter and
α-DYRK1A-Nter antibodies (detailed in Additional file 2:
Figure 2) we evidenced decreased DYRK1A staining inten-
sity using both antibodies in AD cases compared to con-
trols (Additional file 1: Figure 1G,H). In addition, an
astrocytic staining by the α-DYRK1A-Nter antibody was
observed, as confirmed by double-immunofluorescence
and confocal laser (Additional file 1: Figure 1I). Altogether,
these results indicate that DYRK1A undergoes a proteo-
lytic processing in human AD hippocampus leading to the
decrease of DYRK1AFL and the accumulation of DYR-
K1AT thus confirming previous study. Particularly, we
here identified that this pathological mechanism is located
at least in part in astrocytes cells and that it does not affect
the level of DYRK1A kinase activity.
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Leucettine L41 prevents in vitro DYRK1A proteolysis and
limits its interaction with STAT3α
We then tested known DYRK1A inhibitors including
Harmine [13], Leucettine LeuI and Leucettine L41
(also named L41) for their ability to alter DYRK1A
proteolysis. In vitro assays were performed as previ-
ously described [23]. Human hippocampus extracts
were incubated with different concentrations of cal-
cium. A Ca2+ dose-dependent decrease of DYRK1AFL
and increase DYRK1AT were observed while the Ca
2+ che-
lating agent EGTA was used as a control (Fig. 1a). Only
L41 (1 μM) efficiently inhibited DYRK1A proteolysis,
maintaining DYRK1AFL levels and preventing DYRK1AT
formation (Fig. 1b). Similar results were obtained using
mouse hippocampus extracts (Fig. 1c) suggesting that
Leucettine L41 is able to prevent in vitro the DYRK1A
proteolysis in both human and mouse proteins extracts.
In AD hippocampus, DYRK1A proteolysis does
not modify its global kinase activity (see Add-
itional file 1: Figure 1E). To assess whether
DYRK1A C-terminal fraction is necessary for its
selectivity, we performed DYRK1A immunopre-
cipitation using the α-DYRK1A-Nter antibody on
mouse extracts incubated or not with Ca2+ (2mM) and
L41. We then performed western-blots using STAT3α and
IkBα antibodies (Fig. 1d). No binding between both
DYRK1A forms and IkBα was revealed. In con-
trast, we observed a modest interaction between
DYRK1AFL and STAT3α in absence of Ca
2+. This
interaction increased in presence of Ca2+ and
was altered by the addition of L41 (Fig. 1d).
These compelling data suggest that DYRK1AT
has a higher affinity toward STAT3α compared
to DYRK1AFL.
Fig. 1 Identification of Leucettine L41 as a DYRK1A proteolysis inhibitor. a Control human hippocampus extract was incubated at 30 °C during 10min
with various concentrations of CaCl2 (0 to 4,0mM) or with 2mM of EGTA. Proteins were then analyzed by western blot using the α-DYRK1A-Nter
antibody. b Control human hippocampus extract was incubated with 0mM of CaCl2 or 2 mM of CaCl2 and various pharmacological compounds
including Harmine (har), Leucettine LeuI (LeuI) or Leucettine L41 (L41). Proteins were analyzed by western blot using the α-DYRK1A-Nter antibody.
c Control mouse (C57Bl6) hippocampus extract was incubated at 30 °C during 10min with various concentrations of CaCl2 (0 to 4,0 mM) or/with 2mM
of EGTA or/with 2mM of CaCl2 and various concentrations of Leucettine L41 (L41) (0,1 to 2 μM). Proteins were analyzed by western blot using the
α-DYRK1A-Nter antibody. d Control mouse hippocampus extract was incubated at 30 °C during 10min with 0mM of CaCl2 or 2 mM of CaCl2 or 2mM
of CaCl2 with L41 at 1 μM. Protein extracts were then immunoprecipitated with the α-DYRK1A-Nter antibody overnight at 4 °C and immunoprecipitated
protein extract were analyzed by western blot using α-DYRK1A-Nter, STAT3α and IkBα antibodies
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Leucettine L41 treatment prevents proteolytic processing
of DYRK1A in APP/PS1 mice
We then aimed to determine whether L41 could modify
DYRK1A proteolysis in vivo with potential consequences
on AD phenotype. We used 13-month-old APP/PS1
mice with severe and established AD pathology. These
mice present a positive correlation between Aβ accumu-
lation and calpain activity [43]. The treated group re-
ceived intraperitoneal injections of L41, 5 days a week
during one month. Littermates and another cohort of
APP/PS1 mice received injections of the vehicle solution.
Vehicle-treated APP/PS1 mice had lower DYRK1AFL
levels than wild type littermates by western blot analysis
using α-DYRK1A-Cter (p < 0.005) (Fig. 2a, b). They
showed a corresponding two-fold increase in calpain ac-
tivity (p < 0.005) (Fig. 2c), leading to a negative Spear-
man correlation with DYRK1AFL protein levels
(correlation coefficient r = − 0.65, p < 0.021) (Additional
file 3: Figure 3A). L41 treatment fully restored DYR-
K1AFL protein levels in APP/PS1 mice to wild-type
levels (p < 0.005 vs vehicle-treated APP/PS1) (Fig. 2a, b),
independently of a change in calpain activity (p < 0.005
vs vehicle-treated littermates) (Fig. 2c). Thus, there was
no significant correlation between DYRK1AFL protein
levels and calpain activity (correlation coefficient − 0.43,
ns) (Fig. 2d). In contrast, protein levels of various ki-
nases including GSK3β exhibited no change between lit-
termates, vehicle-treated APP/PS1 and L41-treated APP/
PS1 (Additional file 3: Figure 3B). No differences in total
DYRK1A kinase activity was observed among the three
experimental groups (Fig. 2e). Levels of phosphorylated
forms of Tau protein at Thr 212 or Thr 231 and APP pro-
tein at Thr 668 which are described as epitopes targeted
by DYRK1A were not decreased by Leucettine L41 treat-
ment (Additional file 4: Figure 4A and B).
Immunohistochemical analysis using both antibodies
(α-DYRK1A-Cter and α-DYRK1A-Nter) showed lower
DYRK1A staining in the hippocampi of vehicle-treated
APP/PS1 mice compared to littermates for both anti-
bodies, confirming biochemical analysis. Strikingly, treat-
ment of APP/PS1 mice with L41 restored DYRK1A
staining levels in the hippocampus to those of wild-type
mice. Most pyramidal neurons in the CA1 region and
interneurons in the Stratum Radiatum (StrR) exhibited
DYRK1A staining in littermates and APP/PS1 mice
treated or not with L41 (Fig. 2f and Fig. 2g, respectively).
In contrast, additional staining by the α-DYRK1A-Nter
antibody was observed in the cytosol of hippocampal as-
trocytes of vehicle-treated APP/PS1 mice (Fig. 2g). This
was confirmed by double-immunofluorescence and con-
focal microscopy using both anti-DYRK1A antibodies
and an anti-GFAP antibody (Fig. 2h and i). The
α-DYRK1A-Cter antibody, which targets only the DYR-
K1AFL forms, showed only marginal co-localization
between GFAP and DYRK1AFL in all mice groups, as re-
vealed by the level of DYRK1AFL in GFAP-positive cells,
which was the same for all three groups (Fig. 2h). The
α-DYRK1A-Nter antibody, which targets both DYR-
K1AFL and DYRK1AT, showed strong co-localization
between GFAP and DYRK1AFL/DYRK1AT in the hippo-
campi of vehicle-treated APP/PS1 mice. In contrast,
there was only negligible co-localization in wild-type
littermates and Leucettine L41-treated APP/PS1 mice.
The level of DYRK1A in GFAP-positive cells of
vehicle-treated APP/PS1 mice was higher than that in
GFAP-positive cells of littermates and L41-treated APP/
PS1 mice (p < 0.0005 for both) (Fig. 2i). These findings
confirm our previous results in human samples and indi-
cate that L41 can prevent in vivo DYRK1A processing
without changing DYRK1A or calpain activities.
Leucettine L41 treatment prevents STAT3α
phosphorylation and reduces pro-inflammatory cytokines
release in APP/PS1 mice
After showing in vitro an increased affinity of DYR-
K1AT toward STAT3ɑ (see Fig. 1), we evaluated L41
influence on astrocytes and STAT3ɑ phosphorylation
state in APP/PS1 mice. We first assessed GFAP and
vimentin protein levels in the hippocampus by west-
ern blot. As expected, both GFAP and vimentin levels
were increased in APP/PS1 mice hippocampi but
were not affected by L41 treatment (p < 0.05 and p <
0.005 respectively) (Fig. 3a). We confirmed no alter-
ation of the astrocytes recruitment around the amyl-
oid plaques in APP/PS1 treated with L41 (Fig. 3b).
STAT3ɑ as its phosphorylated form [phospho- STAT3α
(Tyr705)] was increased in vehicle-treated APP/PS1
relative to littermates mice (p < 0.05 and p < 0.0005 re-
spectively). Interestingly, L41-treated APP/PS1 exhib-
ited lower phospho-STAT3α levels compared to
vehicle-treated APP/PS1 mice (p < 0.0005), thereby
leading to a restored ratio pSTAT3ɑ/STAT3ɑ similar to
littermates (Fig. 3c). STAT3 is an important signaling
molecule for cytokines and growth factor receptors
production [7, 18] and has been associated with
pro-inflammatory cytokines expression such as IL-1β
and TNF-ɑ [6]. We measured by ELISA these
pro-inflammatory cytokines levels released in part by
reactive astrocytes. Higher concentrations of IL-1β,
IL-12 and TNF-ɑ were measured in APP/PS1 mice
compared to littermates (p < 0.05, p < 0.005, and p < 0.05,
respectively). These levels were reversed by L41 treatment
(p < 0.05, p < 0.005, and p < 0.05, respectively, for L41 vs
vehicle-treated APP/PS1 mice) (Fig. 3d). Collectively,
these data demonstrate that DYRK1AT forms participate
to astrocyte inflammatory cytokines production through a
STAT3ɑ pathway activation.
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Fig. 2 (See legend on next page.)
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Leucettine L41 treatment promotes microglia recruitment
around amyloid plaques in APP/PS1 mice
In response to brain injury, crosstalk between astro-
cytes and microglial cells is driven in part by inflam-
matory mediators [28]. Using confocal microscopy and
double-immunofluorescence, we observed increased
activated microglia (IBA1 staining) around amyloid-β
plaques in L41-treated APP/PS1 mice compared to
vehicle-treated APP/PS1 mice (p < 0.05) (Fig. 4a-b).
Western blot analysis did not reveal differences in
IBA1 protein levels. However, levels of CD68, IDE and
TREM2, microglial markers involved in amyloid-β
clearance, were increased in L41-treated APP/PS1
mice (p < 0.0005, p < 0.05, and p < 0.05, respectively)
(Fig. 4c-d). TREM2 increase was confirmed in micro-
glial cells of L41-treated APP/PS1 mice by immunohis-
tochemistry and was associated with an amyloid
staining suggesting that L41 promotes amyloid-β clear-
ance by microglia (Fig. 4e). Because of the well-known
roles of CD68, IDE and TREM2 in Aβ phagocytosis
and degradation [19, 38], we evaluated the effects of
L41 on soluble and aggregated forms of Aβ in APP/
PS1 mice hippocampi. Neither soluble Aβ40 and Aβ42
concentrations were significantly different between
L41- and vehicle-treated APP/PS1 mice (Fig. 4f ). In
contrast, we observed a significant decrease of the
amyloid-β load in the hippocampi of L41-treated APP/
PS1 mice (p = 0.049) (Fig. 4g). Altogether, these results
demonstrate that L41 treatment promotes microglia
recruitment around Aβ plaques, increases levels of
proteins involved in amyloid-β clearance and leads to
decreased amyloid load.
Leucettine L41 treatment rescues synaptic and memory
impairments in APP/PS1 mice
APP/PS1 mice exhibit decreased long-term potentiation
(LTP) of synaptic transmission associated with impaired
learning and memory [12]. It has been reported that neu-
roinflammation mechanisms and in particular immune
diffusible mediators such as cytokine influence synaptic
transmission, plasticity and thereby memory [2, 10]. We
explored whether L41 treatment (daily injection from age
13 to 14months) could rescue LTP and cognitive deficits.
As expected, APP/PS1 treated with vehicle (n = 13 slices/
N = 5 mice) exhibited impaired LTP relative to littermates
treated with the vehicle solution (n = 11 slices/N = 4 mice)
(p < 0.0005) (Fig. 5a, b). L41-treated APP/PS1 mice exhib-
ited improved LTP (p < 0.0005) relative to APP/PS1 mice
that received vehicle injections. LTP generated in
L41-treated APP/PS1 mice was still significantly lower
compared to littermates (p < 0.0005), suggesting that syn-
aptic plasticity measured by the LTP was partially rescued
by the L41 treatment. To evaluate whether improved syn-
aptic plasticity was also reflected at the behavioral level,
we tested the mice by the Morris water-maze and the
Y-maze tasks (Fig. 5c-f). Spatial learning and long-term
memory were assessed using the Morris water maze para-
digm (Fig. 5c-e). All mice progressively learned the plat-
form position during the learning sessions, as
demonstrated by a decrease in the time required to reach
the platform over the five days of training. Vehicle-treated
APP/PS1 mice exhibited a reduced learning ability relative
to littermates (p = 0.02), whereas L41-treated APP/PS1
mice were statistically undistinguishable from littermate
controls (ns) (Fig. 5c, d). During the 72-h probe test,
(See figure on previous page.)
Fig. 2 L41 treatment prevents DYRK1A proteolysis in APP/PS1 mice hippocampus. a, b Western blot of hippocampus from APP/PS1 mice or
littermates treated with vehicle or L41, showing lower levels of DYRK1A (90 kDa) immunoblotting with the α-DYRK1A-Cter antibody in vehicle-treated
APP/PS1 mice (n = 6) compared to littermates (n = 6) (One-way ANOVA, p < 0.005). DYRK1A protein levels in L41-treated APP/PS1 mice (n = 7) were
higher than in vehicle-treated APP/PS1 mice (One-way ANOVA, p < 0.005) and similar to what observed in littermates (One-way ANOVA, ns). c Calpain
activity assessed by a fluorescent method, showing higher calpain activity in hippocampus from both vehicle-treated (n = 6) and L41-treated APP/PS1
mice (n = 7) compared to littermates (n = 6) (One-way ANOVA, p < 0.05 for both). There was no significant difference between L41-treated and
vehicle-treated APP/PS1 mice (One-way ANOVA, ns). d DYRK1A protein levels did not correlate with calpain activity (r2 = 0.43; ns). e HPLC assay for total
endogenous DYRK1A activity showing no differences between hippocampus from littermates (n = 9) and vehicle- or L41-treated APP/PS1 mice
(n = 9 and 8, respectively) (One-way ANOVA, ns). f Representative images from immunohistochemical staining using the α-DYRK1A-Cter antibody, of
hippocampal slices from littermates, vehicle- and L41-treated APP/PS1 mice, showing neuronal staining in the CA1 and Stratum Radiatum (StrR)
regions (see enlargement at the bottom). g Representative images from immunohistochemical staining, using the α-DYRK1A-Nter antibody, of
hippocampal slices, showing neuronal staining for L41-treated APP/PS1 mice and littermates in the CA1 and Stratum Radiatum (StrR) regions. Neuronal
staining was observed in both the CA1 and StrR regions, whereas additional astrocyte staining was mostly observed in the Stratum Radiatum (StrR)
region of vehicle-treated APP/PS1 mice. h Laser confocal microscopy showing double staining using α-DYRK1A-Cter (red) and anti-GFAP (green)
antibodies. There were no differences in α-DYRK1A-Cter staining in GFAP positive cells between littermates (n = 6, astrocytes = 73), vehicle- (n = 6,
astrocytes = 90), and L41-treated APP/PS1 mice (n = 6, astrocytes = 85) (One-way ANOVA, ns). i Laser confocal microscopy showing double staining
using α-DYRK1A-Nter antibody (red) and anti-GFAP (green). α-DYRK1A-Nter staining was higher in the GFAP positive area in vehicle-treated APP/PS1
mice (n = 6, astrocytes = 105) compared to littermates (n = 6, astrocytes = 50) (One-way ANOVA, p < 0.0005). α-DYRK1A-Nter immunoreactivity was
lower in the GFAP positive area of L41-treated (n = 6, astrocytes = 83) than vehicle-treated APP/PS1 mice (One-way ANOVA, p < 0.0005). Data represent
the mean ± SEM and were analyzed by one-way ANOVA followed by Tukey’s post hoc test. Significant differences between littermates and
vehicle-treated APP/PS1 mice are indicated by *p < 0.05, **p < 0.005 and ***p < 0.0005. Significant differences between vehicle- and L41-treated
APP/PS1 mice are indicated by #p < 0.05, ##p < 0.005 and ###p < 0.0005
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vehicle-treated APP/PS1 mice spent less time in the target
quadrant than littermates (p < 0.05) (Fig. 5e). In contrast,
L41-treated APP/PS1 mice spent more time in the tar-
get quadrant compared to vehicle-treated APP/PS1
mice (p < 0.005) but not different compared to litter-
mates (ns). We also used the Y-maze paradigm to
evaluate the spatial working memory which is mediated
by hippocampus but also prefrontal cortex [47](Fig. 5f ).
Vehicle-treated APP/PS1 mice did not travel more
distance in the new arm compared to the familiar start-
ing arm, suggesting an impaired working memory (ns).
In contrast, vehicle-treated littermates exhibited a spatial
preference for the new arm (p < 0.05) whereas L41-treated
APP/PS1 mice tended to exhibit similar behavior (p = 0.06)
(Fig. 5f). Taken together, these results suggest that L41
treatment alleviates synaptic plasticity impairments and
rescues memories defects in aged APP/PS1 mice
(14-month-old) with well-established cognitive deficits.
Fig. 3 L41 treatment prevents DYRK1AT accumulation in astrocytes and decreases phosphorylation of STAT3α and the release of pro-
inflammatory cytokines. a Representative western blot of mouse hippocampus showing higher levels of GFAP and vimentin in vehicle- (n = 6)
and L41- (n = 7) treated APP/PS1 mice than in littermates (n = 6) (One-way ANOVA; GFAP: p < 0.05 and p < 0.005, respectively; vimentin: p < 0.005
and p < 0.0005, respectively). There were no statistical differences between L41- and vehicle-treated APP/PS1 mice (One-way ANOVA, ns and ns).
b Laser confocal microscopy showing double staining, using anti-4G8 (white) and anti-GFAP (green) antibodies, of hippocampal slices from
vehicle- (n = 6, plaques = 39) or L41- (n = 6, plaques = 38) treated APP/PS1 mice. There were no differences in GFAP (green) immunoreactivity
around amyloid plaques (white) between vehicle- and L41-treated APP/PS1 mice (t-test, ns). c Representative western blot of hippocampus from
mice showing higher phospho-STAT3α / STAT3α ratio in vehicle- treated APP/PS1 mice compared to littermates and L41-treated APP/PS1 mice
(One-way ANOVA; pSTAT3α: p < 0.0005 and p < 0.0005, respectively; STAT3α: p < 0.05 and ns, respectively; pSTAT3α / STAT3α: p < 0.0005 and
p < 0.0005, respectively) (d) ELISA quantification (MSD immunoassay) in samples from hippocampus of littermates, vehicle- and L41-treated APP/
PS1 mice (n = 4, 6, and 7 mice per group, respectively). Vehicle-treated APP/PS1 mice had higher IL-1β, IL-12 (IL-12p70) and TNF-α concentrations
than in littermates (One-way ANOVA: IL-1β and TNF-α, p < 0.05; IL-12p70, p < 0.005). L41-treated APP/PS1 mice had lower IL-1β, IL-12 and TNF-α
concentrations than vehicle-treated APP/PS1 mice (One-way ANOVA: IL-1β, and TNF-α, p < 0.05; IL-12p70, p < 0.005). Data represent the mean ±
SEM and were analyzed by one-way ANOVA followed by Tukey’s post hoc test or Student’s t-test. Significant differences between littermates and
vehicle-treated APP/PS1 mice are indicated by *p < 0.05, **p < 0.005 and ***p < 0.0005. Significant differences between vehicle- and L41-treated
APP/PS1 mice are indicated by #p < 0.05, ##p < 0.005 and ###p < 0.0005
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Fig. 4 L41 treatment promotes microglial cells recruitment leading to a decrease in aggregated amyloid load. a Laser confocal microscopy
showing double staining, using 4G8 antibody (white) and anti-IBA1 (red), of hippocampal slices from vehicle- (n = 6, plaques = 79) or L41- (n = 6,
plaques = 77) treated APP/PS1 mice. b Increased IBA1 immunoreactivity around amyloid plaque of L41-treated APP/PS1 mice, compared to
vehicle-treated APP/PS1 mice, was observed (t-test, p < 0.05). c Western blot of hippocampus from vehicle (n = 6) or L41 (n = 7) treated APP/PS1
mice, showing levels of IBA1, CD68, IDE, and TREM2. d IBA1 protein levels were not statistically different in L41-and vehicle-treated APP/PS1 mice
(t-test, ns). CD68, IDE, and TREM2 protein levels were increased in L41-treated compared to vehicle-treated APP/PS1 mice (CD68: t-test, p < 0.005;
IDE: t-test, p < 0.05; TREM2: t-test, p < 0.005). e Laser confocal microscopy showing IBA1 positive cells with increased TREM2 protein and
colocalization with Aβ species (4G8) in L41-treated compared to vehicle-treated APP/PS1 mice. f ELISA quantification of soluble Aβ40 and Aβ42
(MSD immunoassay) in vehicle- and L41-treated APP/PS1 mice hippocampus (n = 6/7 mice per group). There was no statistical differences
between L41- and vehicle-treated APP/PS1 mice. g Laser confocal microscopy showing double staining with 4G8 antibody (white) and DAPI
(blue), of hippocampal slices from vehicle- (n = 6) or L41- (n = 6) treated APP/PS1 mice. Area covered by the plaques was decreased in the
hippocampus of L41-treated compared to vehicle-treated APP/PS1 mice (t-test, p < 0.05). Data represent the mean ± SEM and were analyzed by
one-way ANOVA, followed by Tukey’s post hoc test or Student’s t-test. Significant differences between vehicle- and L41-treated APP/PS1 mice are
indicated by #p < 0.05, ##p < 0.005, and ### p < 0.0005
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Fig. 5 (See legend on next page.)
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Discussion
The present study provides compelling evidence for
DYRK1A involvement in AD and describes a new mech-
anism through which DYRK1A modulation contributes
to AD pathology. We first describe a proteolytic process-
ing of DYRK1A in the hippocampus of AD patients and
APP/PS1 mice reducing level of full-length form of
DYRK1A (DYRK1AFL) and producing truncated forms
(DYRK1AT). The increase of DYRK1A kinase activity
was suspected to contribute to AD. However, we dem-
onstrate that this proteolysis is not associated with
modification of the global DYRK1A kinase activity but
affect its specificity. DYRK1AT forms exhibit increased
affinity toward STAT3α, an activator of neuroinflamma-
tion. We then show that inhibiting DYRK1A proteolysis
through the peripheral administration of Leucettine L41
in APP/PS1 mice is associated with increased number of
phagocytic-microglia around amyloid-β deposits and re-
duction of the plaque load. This is associated to improved
synaptic plasticity and reduced cognitive and memory def-
icits in APP/PS1 mice. Specific inhibitors of DYRK1A pro-
teolysis could be therapeutic interest for AD.
The DYRK1A gene is located on chromosome 21
(21q22.2), a region known as the Down- Syndrome Crit-
ical Region (DSCR) [9]. People living with Down Syn-
drome (DS) have higher prevalence to develop AD
pathology primarily due to overexpression of the APP
gene on chromosome 21 [17]. In addition, various evi-
dence supports DYRK1A as a potential key player in AD
progression and as a valid therapeutic target for AD
[3, 35]. However, no direct link has been shown be-
tween the kinase activity of DYRK1A and AD. Re-
cently, decreased DYRK1AFL and increased DYRK1AT
forms have been reported in the frontal and temporal
cortex of AD patients (Braak V-VI/Tangles score = 14)
through upregulated calpain I activity, the major cal-
pain isoform in brain [23]. We confirm this observa-
tion in hippocampus from severely affected AD
patients (Braak V-VI, Thal IV-V). We show for the
first-time decreased levels of DYRK1AFL forms in
APP/PS1 mice, together with increased DYRK1AT
forms and increased calpain activity.
DYRK1A has a long kinase domain, followed by a
PEST region, and histidine-repeat and serine/threoni-
ne-rich domains [24]. PEST sequences are rich in the
amino acids proline (P), glutamate (E), serine (S) and
threonine (T), and their presence is correlated with rapid
protein turnover due to proteasome-mediated destruc-
tion [32]. Proteolysis of DYRK1A by calpains probably
occurs within the PEST domain [23] as shown in other
proteins [32]. Beyond the PEST sequence, the
C-terminus domain is the target of other proteins which
negatively modulate DYRK1A kinase activity [49]. In nu-
merous protein kinases, non-catalytic domains partici-
pate in the kinase specificity [44]. In our study, we
provide evidences that the deletion of the C-terminal re-
gion does not affect kinase activity of DYRK1A but in-
creases its affinity toward STAT3α.
(See figure on previous page.)
Fig. 5 L41 treatment improves synaptic plasticity and prevents behavioral deficits in APP/PS1 mice. a, b Long-term potentiation (LTP) was
induced by delivering theta-burst stimulations to hippocampal CA3-CA1 synapses after 20 min of baseline recordings. Slices from vehicle-treated
APP/PS1 mice exhibited deficits in LTP expression relative to littermates. The magnitude of LTP observed in L41-treated APP/PS1 mice was higher
than that in vehicle-treated APP/PS1 mice, but lower than in littermates. b Summary bar graph showing the average potentiation represented as
the percentage from 30 to 60min after theta-burst stimulation. Slices from vehicle-treated APP/PS1 mice showed a mean deficit of LTP (137.7 ± 0.163)
relative to that of littermates (153.5 ± 0.211) (One-way ANOVA, p < 0.0005). The mean LTP of L41-treated APP/PS1 mouse slices (146.8 ± 0.243) was
higher than that of vehicle-treated APP/PS1 mice (One-way ANOVA, p < 0.0005), but lower than that of littermates (One-way ANOVA, p < 0.0005).
n = number of slices, N = number of mice. Significant differences between littermates and APP/PS1 injected with vehicle are indicated by
*** p < 0.0005. Significant differences between vehicle- and L41-treated APP/PS1 mice are indicated by ###p < 0. (c, d, e) Spatial learning and long-term
memory were evaluated using the Morris water maze paradigm on littermates (n = 12), vehicle- (n = 7) and L41- (n = 7) treated APP/PS1 mice.
c Representative occupancy plots during acquisition show a more random search strategy for vehicle- than L41-treateted APP/PS1 mice and
littermates. d Escape latency of vehicle-treated littermate controls or vehicle- or L41-treated APP/PS1 mice. The time to reach the platform was
different between the groups (Two-way ANOVA: Group effect: F2.110 = 3.68, p = 0.028; Time effect: F4.110 = 7.23, p < 0.0001; Group x Time interaction:
F8.110 < 1, ns). Vehicle-treated APP/PS1 mice were impaired relative to vehicle-treated littermate controls (p = 0.02). L41-treated APP/PS1 mice were
statistically indistinguishable from littermate controls (p = ns). Significant differences between littermates and vehicle-treated APP/PS1 mice are
indicated by *p < 0.05. e Probe trial performance at 72 h. (Two-way ANOVA, Group effect: F2.46 = 1.315, p = ns; quadrant effect: F1.46 = 12.58, p = 0.009;
Group x quadrant interaction effect: F2.46 = 5.27, p = 0.0087). Vehicle-treated APP/PS1 mice were impaired relative to vehicle-treated littermates
(p < 0.05). L41 treatment rescued this memory impairment (p < 0.005), confirmed by a preference for the trained target quadrant. Target quadrant (TQ)
and other quadrants (OQ). Bottom: representative occupancy plots during 72 h-probe test show a random search strategy for vehicle-treated APP/PS1
mice, in contrast to both vehicle-treated littermates and L41-treated APP/PS1 mice. Significant differences between the groups are indicated by
*p < 0.05 and ** p < 0.005. Significant differences between the quadrants are indicated by #p < 0.05 and ## p < 0.005. Data represent the mean ± SEM
and were analyzed by one-way or two-way ANOVA followed by Tukey’s post hoc test. f Working memory was evaluated using the Y-maze paradigm
in littermates (n = 9) and vehicle- (n = 8), or L41- (n = 5) treated APP/PS1 mice. The distance covered by the mice in the arms during the evaluation
phase was different between each arm (Two-way ANOVA: Group effect: F2.19 = 1.232; ns; Arm effect: F1.19 = 15.31, p < 0.005; Group x Arm interaction:
F2.19 = 1 .232, ns). Vehicle-treated APP/PS1 mice did not cover significantly more distance in the NA (new arm) than the OA (other arms, including
starting and familiar arms) (Two-way ANVOVA, ns). Littermates and L41-treated APP/PS1 mice covered more distance in the new arm than in the other
arms (p < 0.05 for both). Significant differences between distance covered in the arms are indicated by # p < 0.05
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Several molecules able to reduce DYRK1A kinase ac-
tivity have been developed [31]. One of them, Leucettine
L41 (L41) is a synthetic analogue of the marine sponge
alkaloid Leucettamine B, identified as an inhibitor of
DYRKs/CLKs [8, 41]. Although L41 prevents DYRK1A
proteolysis in APP/PS1 mice hippocampus, we showed
that this compound does not alter DYRK1A (and Calpain)
activity. Thus, several hypotheses can be considered to ex-
plain L41 effect on DYRK1A: (i) L41 could prevent the
interaction between DYRK1A and calpains by inducing a
conformational change in the kinase, (ii) the DYRK1A/
L41 complex could change its intracellular location and
thereby be isolated from calpains, or (iii) the catalytic ac-
tivity of DYRK1A could be required for calpain-mediated
cleavage. Further experiments are still needed to better
understand the action of L41 on DYRK1A regulation.
Consequently to the prevention of DYRK1A, we showed
a decrease of STAT3α phosphorylation (pSTAT3α) in
APP/PS1 mice. STAT3ɑ is a transcription factor and a
major regulator of cytokine production [18]. The tyrosine
phosphorylation is required for its activation and STAT3α
are remarkably activated in APP/PS1 mice [7]. Inhibition
of STAT3α phosphorylation attenuates Aβ-induced neur-
onal death [45]. Our results indicate that a normalization
of pSTAT3ɑ levels by L41 restores pSTAT3α/STAT3α ra-
tio and may participate to the following events: (i) de-
creased release of key inflammatory mediators such as
IL-1β, TNF-α and IL-12, (ii) increased microglial cells re-
cruitment around amyloid plaques, and (iii) decrease of
the amyloid-β burden. The immune system, driven by in-
flammatory mediators, influences AD progression [19]. In
particular, TNF-α has been described to have a major im-
pact in AD. Indeed, increased TNF-α in serum is associ-
ated with a worsen cognitive decline in AD [21] and
elevated concentrations of TNF-α in CSF increase the
probability to evolve from a mild cognitive impairment
(MCI) stage to dementia [42]. In addition, these molecules
have a strong impact on microglial dysfunction [5, 40].
Emerging evidences suggest that microglial activation
plays a crucial role in AD [16]. Activated microglia have
receptors that can uptake and clear Aβ and this may limit
the formation of plaques through phagocytosis of Aβ spe-
cies [38]. In APP/PS1 mice, proinflammatory cytokines
(IL-1β and TNF-α) increase in concentration with age and
down regulate genes involved in amyloid-β clearance [20].
Therefore, microglia become progressively dysfunctional
and display altered activation as the disease progresses.
Our data show that L41 treatment in APP/PS1 mice pro-
motes a moderate reduction of the amyloid load, which
may be explained by the induction of an activated micro-
glia phenotype expressing increased levels of TREM2
(triggering receptor expressed on myeloid cells 2) and IDE
(insulin degrading enzyme), two microglial proteins that
have been demonstrated to regulate Aβ deposition in AD
mouse models [12, 14, 48]. A previous study reported that
inhibition of calpains mitigates AD pathology and cogni-
tive decline in 3xTgAD mice [30]. We show that L41 has
no effect on calpains activity which remains elevated in
APP/PS1 mice. Interestingly, selective effect on
DYRK1A proteolysis by Leucettine L41 improved syn-
aptic plasticity measured by LTP and rescued spatial
learning, working memory and long-term memory im-
pairments in APP/PS1 mice tested with the Y-maze and
the Morris water maze tasks at 14 months of age. These
findings suggest that preventing DYRK1A proteolysis is
sufficient to observe disease-modifying effects in this
mouse model. This is supported by comparative evalu-
ation of another synthetic analogue of Leucettamine B,
the LeuI in APP/PS1 mice at the same age. As showed
in vitro (see Fig. 1b), LeuI is unable to prevent DYRK1A
proteolysis. Using similar experimental conditions, we
compared LeuI and L41-treated APP/PS1 mice
(Additional file 5: Figure 5A-F). No rescue of DYRK1AFL
levels and DYRK1AT in astrocytes or no significant de-
crease of pro-inflammatory cytokines were observed in
LeuI treated animals (Additional file 5: Figure 5A-C).
Moreover, no decrease of the amyloid plaque burden and
no improvement of the spatial / long-term memory were
measured (Additional file 5: Figure 5D-F). These data con-
firm the role of DYRK1A proteolysis in AD progression
and the potential interest of this mechanism as a new
therapeutic target to counteract the disease.
Conclusion
In conclusion, we provide several evidences that DYRK1A
is proteolyzed in both AD patients and APP/PS1 mice. We
show that truncated forms of DYRK1A accumulate in as-
trocytes without consequences on its kinase activity. How-
ever, kinase specificity of truncated DYRK1A is reduced
leading to increase its affinity toward STAT3α, a major
regulator of inflammation We demonstrate that decreas-
ing production of DYRK1A truncated forms by Leucettine
L41 in an AD-like mouse model, reduces levels of inflam-
matory cytokines, improves clearance of amyloid-β pla-
ques through microglia recruitment and activation, and
consequently improves synaptic plasticity and memory.
These data confirm the interest of L41 and eventually
other inhibitors of DYRK1A proteolysis for AD.
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